Instil Bio, Inc. TIL
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -38.18%
- 1 year
- -60.37%
- Open
- 6.74
- Prev close
- 6.83
- Mkt cap
- 46.12M
- Vol
- 25.23K
- Avg vol
- 25.64K
- EPS
- -4.43
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.51
- High
- 6.87
- Forward P/E
- -1.80
- Beta
- 1.74
- Short ratio
- 2.29
- Inst. own
- 80.70%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 13, 2024
- 50-d avg
- 29.13
- 200-d avg
- 20.96
- 1y target
- 100.33
News
2 days ago globenewswire.com
Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC)
24.6% Objective Response Rate (ORR) in 69 Patients with Non-Squamous mNSCLC, Consistent with Previously Reported Results IOV-LUN-202 Cohorts 1 and 2 Are Completing Enrollment and Support a Planned…
3 days ago globenewswire.com
Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine Strategy
Live Webcast at 8:30 a.m. ET on Thursday, October 29, 2026 PHILADELPHIA, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on…
5 days ago globenewswire.com
Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026
50% Confirmed Objective Response Rate (ORR) with All Responses Ongoing in an Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2026 Unprecedented Efficacy in Both…
1 week ago globenewswire.com
Iovance Presents New Data at ESMO 2026 Demonstrating Deep, Durable Responses with Lifileucel TIL Cell Therapy Plus Pembrolizumab in Frontline Advanced Melanoma
62.5% Confirmed Objective Response Rate (ORR) and 29.2% Complete Response (CR) Rate in Final Phase 2 Analysis Median Overall Survival (OS) Not Reached at More than 4 Years of Median Follow-up Oral…
1 week ago globenewswire.com
Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026
Iovance Advances TIL Cell Therapy into a New Chapter in Solid Tumor Treatment Two Oral Presentations to Showcase Deep, Durable Responses with TIL Cell Therapy in Frontline Melanoma and Previously…
4 weeks ago gurufocus.com
Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting
Obsidian Therapeutics, Inc. (âObsidianâ) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop
1 month ago marketbeat.com
Iovance Maps TIL Therapy Expansion After Record Revenue and Margin Gains
Iovance Biotherapeutics NASDAQ: IOVA said it is expanding its tumor-infiltrating lymphocyte, or TIL, therapy platform across multiple solid-tumor indications after reporting a record second quarter…
2 months ago zacks.com
5 Biotech Stocks Worth Adding to Your Portfolio Now
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and…
-
2 months ago benzinga.com
Instil Bio Q2 Adj. EPS $(0.45) Misses $(0.43) Estimate
Instil Bio (NASDAQ:TIL) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.43) by 4.65 percent. This is a 84.37 percent increase over losses of $(2.88)…
2 months ago globenewswire.com
Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
DALLAS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its second…
2 months ago gurufocus.com
Obsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 Million
Obsidian Therapeutics, Inc. (âObsidianâ) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop
3 months ago seekingalpha.com
Iovance: The Worst May Be Behind This TIL Pioneer (Upgrading To Buy)
Iovance Biotherapeutics is showing steady operational and financial progress, supporting a speculative Buy rating upgrade. Q1 revenue reached $71.4M, with Amtagvi generating $60M; the sequential dip…
5 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
5 months ago globenewswire.com
Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001
Next-Generation Platform Expands into Solid Tumors Representing 100,000+ U.S. Deaths Annually SAN CARLOS, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a…
5 months ago globenewswire.com
Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
DALLAS, May 15, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its first…
-
7 months ago benzinga.com
Earnings Scheduled For March 27, 2026
Earnings Scheduled For March 27, 2026
-
7 months ago benzinga.com
Instil Bio Q4 Adj. EPS $(0.97) Beats $(2.03) Estimate
Instil Bio (NASDAQ:TIL) reported quarterly losses of $(0.97) per share which beat the analyst consensus estimate of $(2.03) by 52.15 percent. This is a 10.19 percent increase over losses of $(1.08)…
7 months ago globenewswire.com
Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Company evaluating potential acquisitions and in-licensing opportunities to drive next phase of strategic development Cash position of $76.3 million as of December 31, 2025 expected to fund current…
8 months ago globenewswire.com
Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas
50% Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE…
8 months ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
NEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ: TIL). Such investors are advised to…
9 months ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL). Such investors are advised to…
9 months ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ: TIL). Such investors are advised to…
9 months ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL). Such investors are advised to…
9 months ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ: TIL). Such investors are advised to…
9 months ago benzinga.com
Dow Jumps Over 400 Points; US Services Activity Falls In December
Dow Jumps Over 400 Points; US Services Activity Falls In December
9 months ago benzinga.com
Instil Bio Pulls Plug On Lead Drug Development
Instil Bio stock falls after the company ends development of its lead cancer drug and exits a licensing deal, raising new questions about its pipeline and next steps.
9 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
9 months ago benzinga.com
US Stocks Mixed; Nasdaq Gains Over 50 Points
US Stocks Mixed; Nasdaq Gains Over 50 Points
-
11 months ago benzinga.com
Instil Bio Q3 Adj. EPS $(1.75) Beats $(2.35) Estimate
Instil Bio (NASDAQ:TIL) reported quarterly losses of $(1.75) per share which beat the analyst consensus estimate of $(2.35) by 25.69 percent. This is a 31.37 percent increase over losses of $(2.55)…
-
1 year ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Instil Bio, Maintains $125 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $125 price target.
-
1 year ago benzinga.com
Instil Bio Says ImmuneOnco Biopharma Presents Preliminary Efficacy And Safety Data Of '2510 As Monotherapy In Phase 1 Study Of Patients In China With Previously Treated Sq-NSCLC At 2025 WCLC
ORR of 35% in previously treated squamous NSCLC patients with responses across PD-L1 TPS scoresDifferentiated structure of ‘2510 potentially results in best-in-class monotherapy activity in 2L+ NSCLC…
-
1 year ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Instil Bio, Maintains $125 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $125 price target.
-
1 year ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Instil Bio, Maintains $125 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $125 price target.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
1 year ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Instil Bio, Maintains $125 Price Target
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $125 price target.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
1 year ago benzinga.com
JMP Securities Reiterates Market Perform on Instil Bioto Market Perform
JMP Securities analyst Reni Benjamin reiterates Instil Bio (NASDAQ:TIL) from Market Perform to Market Perform.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
1 year ago benzinga.com
HC Wainwright & Co. Maintains Buy on Instil Bio, Lowers Price Target to $105
HC Wainwright & Co. analyst Mitchell Kapoor maintains Instil Bio (NASDAQ:TIL) with a Buy and lowers the price target from $110 to $105.
-
1 year ago benzinga.com
Instil Bio, ImmuneOnco Advance Lung Cancer Drug '2510 With New Trials in China and US Plans Ahead
Instil Bio, Inc. (NASDAQ:TIL, ", Instil", ))) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, "ImmuneOnco"), today announced clinical trial updates of ‘2510 and NSCLC clinical…
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
1 year ago benzinga.com
Why Pegasystems Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
Why Pegasystems Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
Instil Bio Q1 Adj. EPS $(1.32) Beats $(2.59) Estimate
Instil Bio (NASDAQ:TIL) reported quarterly losses of $(1.32) per share which beat the analyst consensus estimate of $(2.59) by 49.03 percent. This is a 44.77 percent increase over losses of $(2.39)…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
1 year ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Instil Bio, Maintains $110 Price Target
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $110 price target.
-
1 year ago benzinga.com
Instil Bio Q4 2024 GAAP EPS $(1.82) Beats $(3.22) Estimate, Instil Had $115.1M In Total Cash, Cash Equivalents, Restricted Cash And Marketable Securities, That Is Expected To Fund Its Current Operating Plan Beyond 2026
Instil Bio (NASDAQ:TIL) reported quarterly losses of $(1.82) per share which beat the analyst consensus estimate of $(3.22) by 43.48 percent. This is a 8.54 percent increase over losses of $(1.99)…
-
1 year ago benzinga.com
JMP Securities Reiterates Market Perform on Instil Bioto Market Perform
JMP Securities analyst Chris Muller reiterates Instil Bio (NASDAQ:TIL) from Market Perform to Market Perform.
-
1 year ago benzinga.com
Instil Bio Announces Clinical Progress In China For IMM2510/SYN-2510, A Clinical-Stage PD-L1xVEGF Bispecific Antibody
ImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with chemotherapy in patients with advanced NSCLC in China.